WO2002010436A3 - Prognostic classification of breast cancer - Google Patents

Prognostic classification of breast cancer Download PDF

Info

Publication number
WO2002010436A3
WO2002010436A3 PCT/US2001/023642 US0123642W WO0210436A3 WO 2002010436 A3 WO2002010436 A3 WO 2002010436A3 US 0123642 W US0123642 W US 0123642W WO 0210436 A3 WO0210436 A3 WO 0210436A3
Authority
WO
WIPO (PCT)
Prior art keywords
tumors
breast cancer
mai
prognostic classification
genes
Prior art date
Application number
PCT/US2001/023642
Other languages
French (fr)
Other versions
WO2002010436A2 (en
Inventor
Jan Baak
George L Mutter
Original Assignee
Brigham & Womens Hospital
Jan Baak
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham & Womens Hospital, Jan Baak filed Critical Brigham & Womens Hospital
Publication of WO2002010436A2 publication Critical patent/WO2002010436A2/en
Publication of WO2002010436A3 publication Critical patent/WO2002010436A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Abstract

The invention provides particular sets of genes that are expressed differentially in tumors characterized as high MAI or low MAI tumors. These sets of genes can be used to discriminate between high and low MAI tumors. Diagnostic assays for classification of tumors, prediction of tumor outcome, selecting and monitoring treatment regimens and monitoring tumor progression/regression are also provided.
PCT/US2001/023642 2000-07-28 2001-07-27 Prognostic classification of breast cancer WO2002010436A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22209300P 2000-07-28 2000-07-28
US60/222,093 2000-07-28

Publications (2)

Publication Number Publication Date
WO2002010436A2 WO2002010436A2 (en) 2002-02-07
WO2002010436A3 true WO2002010436A3 (en) 2003-07-03

Family

ID=22830791

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/023642 WO2002010436A2 (en) 2000-07-28 2001-07-27 Prognostic classification of breast cancer

Country Status (1)

Country Link
WO (1) WO2002010436A2 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8846072B2 (en) 2004-09-17 2014-09-30 Durect Corporation Controlled delivery system
US8956644B2 (en) 2006-11-03 2015-02-17 Durect Corporation Transdermal delivery systems
US9233160B2 (en) 2002-12-13 2016-01-12 Durect Corporation Oral drug delivery system
US9555113B2 (en) 2013-03-15 2017-01-31 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
US9592204B2 (en) 2007-12-06 2017-03-14 Durect Corporation Oral pharmaceutical dosage forms

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2799555B1 (en) 2002-03-13 2017-02-22 Genomic Health, Inc. Gene expression profiling in biopsied tumor tissues
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
US7723018B2 (en) * 2002-08-30 2010-05-25 Rigel Pharmaceuticals, Incorporated Methods of assaying for cell cycle modulators using components of the ubiquitin ligation cascade
JP2006515515A (en) * 2002-12-20 2006-06-01 アバロン ファーマシューティカルズ，インコーポレイテッド Amplified cancer target genes useful for diagnostic and therapeutic screening
US20050181375A1 (en) * 2003-01-10 2005-08-18 Natasha Aziz Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of metastatic cancer
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
AU2012206980B2 (en) * 2003-01-15 2015-02-05 Genomic Health, Inc. Gene expression markers for breast cancer prognosis
DE10315834A1 (en) * 2003-03-31 2004-11-18 Hinzmann, Bernd, Dr. Human nucleic acid sequences from pancreatic carcinomas
US7306910B2 (en) 2003-04-24 2007-12-11 Veridex, Llc Breast cancer prognostics
ES2488845T5 (en) 2003-06-24 2017-07-11 Genomic Health, Inc. Prediction of the probability of cancer recurrence
US20060234930A1 (en) * 2003-07-16 2006-10-19 Daria Onichtchouk Use of dg008,dg065,dg210 or dg239 secreted protein products for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome
WO2005021788A1 (en) * 2003-08-28 2005-03-10 Ipsogen Identification of an erbb2 gene expression signature in breast cancer
JP5813908B2 (en) 2004-04-09 2015-11-17 ジェノミック ヘルス， インコーポレイテッド Gene expression markers to predict response to chemotherapeutic agents
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
JP5312024B2 (en) * 2006-06-09 2013-10-09 株式会社ヤクルト本社 Genes involved in immortalization of human cancer cells and their use
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
CA3167217A1 (en) 2020-01-13 2021-07-22 Durect Corporation Sustained release drug delivery systems with reduced impurities and related methods

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996029430A1 (en) * 1995-03-17 1996-09-26 John Wayne Cancer Institute Detection of melanoma or breast metastases with a multiple marker assay
US5622829A (en) * 1993-12-08 1997-04-22 The Regents Of The University Of California Genetic markers for breast, ovarian, and prostatic cancer
WO1999001581A1 (en) * 1997-07-02 1999-01-14 Genzyme Corporation P53 influenced gene expression
WO1999037771A1 (en) * 1998-01-22 1999-07-29 John Wayne Cancer Institute A new human tumor-associated gene

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5622829A (en) * 1993-12-08 1997-04-22 The Regents Of The University Of California Genetic markers for breast, ovarian, and prostatic cancer
WO1996029430A1 (en) * 1995-03-17 1996-09-26 John Wayne Cancer Institute Detection of melanoma or breast metastases with a multiple marker assay
WO1999001581A1 (en) * 1997-07-02 1999-01-14 Genzyme Corporation P53 influenced gene expression
WO1999037771A1 (en) * 1998-01-22 1999-07-29 John Wayne Cancer Institute A new human tumor-associated gene

Non-Patent Citations (15)

* Cited by examiner, † Cited by third party
Title
BEATTIE J ET AL: "AN IMMOBILISED PEPTIDE ARRAY IDENTIFIES ANTIBODIES TO A DISCONTINUOUS EPITOPE IN THE EXTRACELLULAR DOMAIN OF THE BOVINE GROWTH HORMONE RECEPTOR", EUROPEAN JOURNAL OF BIOCHEMISTRY, BERLIN, DE, vol. 239, no. 2, 1996, pages 479 - 486, XP001051806, ISSN: 0014-2956 *
COX C J ET AL: "TUMOR MARKER SENSITIVITY: SINGLE VERSUS MULTIPLE MARKERS IN PATIENTS WITH BREAST CARCINOMA", AMERICAN JOURNAL OF CLINICAL PATHOLOGY, PHILADELPHIA, PA, US, vol. 84, no. 4, 1 October 1990 (1990-10-01), pages 507, XP000576592, ISSN: 0002-9173 *
DATABASE EMBL [online] XP002224495, retrieved from EBI Database accession no. X57522 *
DATABASE EMBL [online] XP002224496, retrieved from EBI Database accession no. Q03518; Q16149 *
DATABASE EMBL [online] XP002224749, retrieved from EBI Database accession no. X13839 *
DATABASE EMBL [online] XP002224750, retrieved from EBI Database accession no. P03996; P04108 *
DE JONG JOHANNES S ET AL: "Expression of growth factors, growth-inhibiting factors, and their receptors in invasive breast cancer. II: Correlations with proliferation and angiogenesis.", JOURNAL OF PATHOLOGY, vol. 184, no. 1, January 1998 (1998-01-01), pages 53 - 57, XP009002528, ISSN: 0022-3417 *
FODOR S P A ET AL: "MULTIPLEXED BIOCHEMICAL ASSAYS WITH BIOLOGICAL CHIPS", NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 364, 5 August 1993 (1993-08-05), pages 555 - 556, XP001019280, ISSN: 0028-0836 *
HARRIS A L ET AL: "GENE THERAPY THROUGH SIGNAL TRANSDUCTION PATHWAYS AND ANGIOGENIC GROWTH FACTORS AS THERAPEUTIC TARGETS IN BREAST CANCER", CANCER, AMERICAN CANCER SOCIETY, PHILADELPHIA, PA, US, vol. 74, no. 3, SUPPL, 1 August 1994 (1994-08-01), pages 1021 - 1025, XP002912451, ISSN: 0008-543X *
JIANG M ET AL: "P21/WAF1/CIP1 AND MDM-2 EXPRESSION IN BREAST CARCINOMA PATIENTS AS RELATED TO PROGNOSIS", INTERNATIONAL JOURNAL OF CANCER, NEW YORK, NY, US, vol. 74, no. 5, 21 October 1997 (1997-10-21), pages 529 - 534, XP001055156, ISSN: 0020-7136 *
KRISHNAN R ET AL: "ELASTIN GENE EXPRESSION IN ELASTOTIC HUMAN BREAST CANCERS AND EPITHELIAL CELL LINES", CANCER RESEARCH, vol. 50, no. 7, 1990, pages 2164 - 2171, XP001121663, ISSN: 0008-5472 *
MARTIN K J ET AL: "LINKING GENE EXPRESSION PATTERNS TO THERAPEUTIC GROUPS IN BREAST CANCER", PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, NEW YORK, NY, US, vol. 41, March 2000 (2000-03-01), pages 311 - 312, XP001026368, ISSN: 0197-016X *
RAO J Y ET AL: "SINGLE CELL MULTIPLE BIOMARKER ANALYSIS IN ARCHIVAL BREAST FINE-NEEDLE ASPIRATION SPECIMENS: QUANTITATIVE FLUORESCENCE IMAGE ANALYSIS OF DNA CONTENT, P53, AND G-ACTIN AS BREAST CANCER BIOMARKERS", CANCER EPIDEMIOLOGY, BIOMARKERS AND PREVENTION, AMERICAN ASSOCIATION FOR CANCER RESEARCH,, US, vol. 7, no. 11, 1998, pages 1027 - 1033, XP001009763, ISSN: 1055-9965 *
SGROI D C ET AL: "IN VIVO GENE EXPRESSION PROFILE ANALYSIS OF HUMAN BREAST CANCER PROGRESSION", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 59, no. 22, 15 November 1999 (1999-11-15), pages 5656 - 5661, XP000994514, ISSN: 0008-5472 *
TANAKA T ET AL: "PROGNOSTIC DISCRIMINATION AMONG NEUROBLASTOMAS ACCORDING TO HA-RAS/TRK A GENE EXPRESSION A COMPARISON OF THE PROFILES OF NEUROBLASTOMAS DETECTED CLINICALLY AND THOSE DETECTED THROUGH MASS SCREENING", CANCER, AMERICAN CANCER SOCIETY, PHILADELPHIA, PA, US, vol. 83, no. 8, 15 October 1998 (1998-10-15), pages 1626 - 1633, XP001027462, ISSN: 0008-543X *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9233160B2 (en) 2002-12-13 2016-01-12 Durect Corporation Oral drug delivery system
US9517271B2 (en) 2002-12-13 2016-12-13 Durect Corporation Oral drug delivery system
US8846072B2 (en) 2004-09-17 2014-09-30 Durect Corporation Controlled delivery system
US8956644B2 (en) 2006-11-03 2015-02-17 Durect Corporation Transdermal delivery systems
US9592204B2 (en) 2007-12-06 2017-03-14 Durect Corporation Oral pharmaceutical dosage forms
US9555113B2 (en) 2013-03-15 2017-01-31 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
US9572885B2 (en) 2013-03-15 2017-02-21 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability

Also Published As

Publication number Publication date
WO2002010436A2 (en) 2002-02-07

Similar Documents

Publication Publication Date Title
WO2002010436A3 (en) Prognostic classification of breast cancer
WO2002009573A3 (en) Prognostic classification of endometrial cancer
WO2004070062A3 (en) Compositions and methods for diagnosing and treating cancers
WO2003021227A3 (en) Methods and compositions useful for diagnosis, staging, and treatment of cancers and tumors
WO2004085621A3 (en) Gene expression in breast cancer
WO2004050707A3 (en) Tumor-specific recognition molecules
WO2002092854A3 (en) Genes expressed in breast cancer as prognostic and therapeutic targets
WO2004061423A3 (en) Compositions and methods for diagnosing and treating colon cancers
WO2006089233A3 (en) Methods and systems for diagnosis, prognosis and selection of treatment of leukemia
EP1910838A4 (en) Cancer specific glycans and use thereof
WO2003004989A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
WO2002059271A3 (en) Gene expression profiles in breast tissue
EP1363920A4 (en) Modified psma ligands and uses related thereto
WO2006119365A3 (en) Composition and methods for cancer diagnosis utilizing the mir 17-92 cluster
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
WO2000028090A3 (en) Diagnostic assay for cancer
WO2005000087A3 (en) Gene products differentially expressed in cancerous colon cells and their methods of use ii
WO2004106495A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
WO2004097052A3 (en) Methods for prognosis and treatment of solid tumors
WO2004060302A3 (en) Methods and compositions for the diagnosis, prognosis, and treatment of cancer
WO2004056874A3 (en) Neuropilin-1 inhibitors
WO2003050243A3 (en) Novel genes encoding colon cancer antigens
WO2003021229A3 (en) Diagnostic and prognostic tests
WO2005119260A3 (en) Methods for predicting and monitoring response to cancer therapy
WO2007033167A3 (en) Compositions and methods for detecting and treating cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)